As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla. , Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on
